Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Association Between Locomotor Muscle Quality and Cardiac Function During Exercise in Heart Failure with Preserved Ejection Fraction
Sharif, Salaheddin M. , Olson, Thomas P. , Smith, Joshua R. , Smith, Joshua R , Smith, Joshua R., Borlaug, Barry A.

European Journal of Heart Failure | November 20, 2024 | Volume: 27 | Issue: 11 | Pages: 2521-2524

10.1002/ejhf.3528 | PMID 39563172 Get It

Enhancing team development in an internal medicine resident continuity clinic
Wingo, Majken T. , Leasure, Emily L. , Wallace, Jocelyn A., Huber, Jill M. , Mathias, Tammy R., Thomas, Kris G., Halvorsen, Andrew J.

Medical Education Online | November 20, 2024 | Volume: 29 | Issue: 1 | Pages: No page available

10.1080/10872981.2024.2430570 | PMID 39563076 Get It

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Mendez, Joe , Cohen, Adam L. , Eckenstein, Midori, Jensen, Randy L. , Burt, Lindsay , Salzman, Karen L. , Chamberlain, Marc C. , Hsu, Henry H. , Hutchinson, Marguerite, Mrugała, Maciej M. , Pelayo, Michael, Raizer, Jeffrey J. , Reardon, David A. , Sterba, Michael, Walbert, Tobias , Wong, Eric T. , Zhang, Chao , Colman, Howard , Mendez, Joe S , Reardon, David A , Walbert, Tobias , Colman, Howard , IWAMOTO, FABIO MASSAITI , Ligon, Keith L , Plotkin, Scott R. , Puduvalli, Vinay K. , West, Brian L.

Neuro-Oncology Advances | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae202 | PMID 39734810 Get It

Abstract Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
Unveiling Disability Accrual Mechanisms in AQP4-IgG–Positive NMOSD
Dinoto, Alessandro , Flanagan, E P , Dinoto, Alessandro , Flanagan, Eoin P.

Neurology | November 19, 2024 | Volume: 103 | Issue: 12 | Pages: No page available

10.1212/wnl.0000000000210096 | PMID 39561310 Get It

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Sullivan, Ryan J. , Najjar, Yana G. , Akkooi, Alexander C. J. van , Menzies, Alexander M, Long, Georgina V, Taylor, Amelia M., Haanen, John, Zijlker, Lisanne P. , Davis, Keith L. , Karanth, Siddharth , Norton, Deborah , Connolly, Lucy, Long, Georgina V. , Karanth, Siddharth , Long, Georgina V , Weber, Jeffrey S. , Haque, Waqas Zia , Markovic, Svetomir N. , Salama, April K.S. , Mehmi, Inderjit , Menzies, Alexander M , Haanen, John B A G , Connolly, Lucy

The Oncologist | November 19, 2024 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyae289 | PMID 39560953 Get It

Abstract Background In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on/after 1L adjuvant CPI. Patients and methods This was a retrospective review of BRAF V600-mutated resected stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally/distantly, were again resected to no evidence of disease, and received dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab/tram (RFS-2), analyzed via Kaplan-Meier methods. Results Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab/tram initiation). Median dab/tram duration was 10.1 months (range: 1 day–22.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9–28.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months. Conclusions Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.
Neuro-Ophthalmic Literature Review
Chen, John J. , Hung, Wei-Che , Jindahra, Panitha , Vaphiades, Michael S., Zhang, Xiaojun , Chen, John J , Mak, Andrew C. Y. , McClelland, Collin M. , Verma, Rashmi , Xie, Jim Shenchu

Neuro-Ophthalmology | November 19, 2024 | Volume: 48 | Issue: 6 | Pages: 464-471

10.1080/01658107.2024.2408954 Get It

Smoking and outcomes in candidates for liver transplantation: Analysis of the Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2)
Cecil, C., Moutchia, Jude , Krowka, Michael J. , Forde, Kimberly A. , Fallon, Michael B. , Al‐Naamani, Nadine , Al-Naamani, Nadine , DuBrock, Hilary M. , Krok, Karen , Kawut, Steven M.

Liver Transplantation | November 19, 2024 | Volume: 31 | Issue: 3 | Pages: 323-332

10.1097/lvt.0000000000000485 | PMID 39560494 Get It

Patients with chronic liver disease commonly have abnormal lung function; however, the impact of smoking on outcomes in these patients is unknown. We hypothesized current or past smoking would be associated with worse survival in patients with advanced liver disease. The Pulmonary Vascular Complications in Liver Disease Study 2 (PVCLD2) was a prospective cohort of patients with advanced liver disease undergoing evaluation for liver transplantation (LT). Patients were classified by self-report as a “non-smoker,” “past smoker,” or “current smoker.” We used Cox proportional hazards models and Fine-Gray models with LT as a competing risk. Models were adjusted for age, sex, body mass index, race, family income, liver disease etiology, and Model for End-Stage Liver Disease-Sodium score. Of the 410 patients included, most (65%) were male and the mean age at enrollment was 56.5 years. One hundred sixty (39%) patients were nonsmokers, 183 (45%) were past smokers, and 67 (16%) were current smokers. In total, 151 (37%) patients received an LT, and 88 (20%) patients died. When compared to nonsmokers, current smokers had a 2.17-fold increase in risk of death overall (95% CI: 1.12–4.18, p = 0.02). There was a 7% increase in overall risk of death for every 5 pack-years increase (95% CI: 1.01–1.13, p = 0.02). With LT as a competing risk, the subdistributional HR of current smokers versus nonsmokers for death was 2.45 (95% CI: 1.31–4.60, p = 0.005). In this model, past smokers displayed a nonsignificant increase in the risk of death compared to nonsmokers (subdistributional HR: 1.58, 95% CI: 0.91–2.72, p = 0.10). Patients with advanced liver disease undergoing evaluation for LT who smoke have an increased risk of death. Smoking cessation could lead to improved overall survival with or without LT.
Association Between Tibiofemoral Bone Shape Features and Retears After Anterior Cruciate Ligament Reconstruction
Bailey, Karsyn N. , Gao, Kenneth T. , Halvorson, Ryan T. , Oeding, Jacob F. , Majumdar, Sharmila, Pedoia, Valentina , Oeding, Jacob F , Lansdown, Drew Anderson

Orthopaedic Journal of Sports Medicine | November 19, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241289096 | PMID 39569414 Get It

Background: A retear after anterior cruciate ligament (ACL) reconstruction remains a common and devastating complication. Knee bone morphology is associated with the risk of ACL injuries, ACL retears, and osteoarthritis, and a combination of tools that derive bone shape from clinical imaging, such as magnetic resonance imaging (MRI) and statistical shape modeling, could identify patients at risk of developing these joint conditions. Purpose: To identify bone shape features before primary ACL reconstruction in patients with an eventual retear compared to those with a known intact ACL graft. Study Design: Case-control study; Level of evidence, 3. Methods: Bone was automatically segmented on 2-dimensional proton density–weighted MRI of the knee in patients at the time of the initial ACL injury using deep convolutional neural networks. Patients with a subsequent retear after reconstruction within 3 years (22 femurs, 19 tibias) were compared with those with an intact ACL graft at 3 years (20 femurs, 22 tibias) using statistical shape modeling to identify preoperative bone shape features predictive of a retear after ACL reconstruction. Results: Statistical shape modeling revealed 2 specific bone shape features (modes) in the femur and 1 mode in the tibia that demonstrated significant differences at the time of the initial injury in patients with subsequent retears. In the femur, a narrower intercondylar notch width, a widened medial condylar width, an increased femoral condylar offset ratio, increased surface area along the lateral femoral condyle relative to the medial condyle, and a more prominent trochlear sulcus at the time of the initial injury were associated with retears after ACL reconstruction. In the tibia, a diminished ACL facet prominence, a squared lateral and medial tibial plateaus, and a broader and flattened tibial spine at the time of the initial injury were associated with retears after ACL reconstruction. Conclusion: Using the automatic bone segmentation pipeline on preoperative MRI, the authors identified bone shape features associated with a retear after ACL reconstruction. The use of this pipeline enables large-scale studies of bone shape on MRI and could predict patients at risk of ACL retears to alter treatment decisions.
Prior immunity to Ureaplasma urealyticum protects against respiratory infection in immunosuppressed mice
Al-Jabri, Maha Y. , Patel, Robin , Fleming, Derek , Patel, Robin , Fleming, Derek

Microbiology Spectrum | November 19, 2024 | Volume: 13 | Issue: 1 | Pages: No page available

10.1128/spectrum.01763-24 | PMID 39560424 Get It

ABSTRACT Ureaplasma species can cause systemic infections in immunocompromised hosts, including lung transplant recipients. Here, we investigated the impact of prior exposure to Ureaplasma urealyticum on the risk of U. urealyticum and Ureaplasma parvum infection in mice subjected to an immunosuppression regimen similar to that administered to solid organ transplant recipients. Mice were immunized with three intramuscular injections of U. urealyticum , with control mice injected with adjuvant only. Following immunization, mice received tacrolimus, mycophenolate mofetil, and methylprednisolone, and then were challenged with U. urealyticum or U. parvum intraperitoneally and intratracheally over 6 days. Relative U. urealyticum antibody levels in plasma were assessed over time, and lungs were harvested at sacrifice for bacterial load quantification, assessed using a color-changing unit assay. U. urealyticum antibody levels were higher in immunized compared with control animals ( P < 0.0001), even when animals were immunosuppressed. U. urealyticum and U. parvum lung burden was reduced in immunized compared with control mice (~6 log 10 reduction for U. urealyticum and <1 log 10 reduction for U. parvum ; P = 0.008 and 0.046, respectively). In summary, this study shows that prior exposure to live U. urealyticum provides some protection against infection with U. urealyticum . IMPORTANCE Ureaplasma -induced hyperammonemia syndrome is a rare but potentially deadly complication of solid organ transplantation, especially lung transplantation. The pathophysiology of this relatively recently recognized condition is poorly understood, and it is unclear what factors may influence patient susceptibility. This study investigates the possible protective effects of prior exposure to Ureaplasma urealyticum in a mouse model subjected to an immunosuppression regimen similar to that given to lung transplant recipients. The findings show that prior exposure could provide protection against Ureaplasma lung infection.
High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease
Hegde, Yash, Lazarus, Sarah , Hollnagel, Fauzia, Caldera, Freddy , Osman, Fauzia , Caldera, Freddy , Farraye, Francis A. , Hayney, Mary S.

Journal of Clinical Gastroenterology | November 19, 2024 | Volume: 59 | Issue: 8 | Pages: 773-779

10.1097/mcg.0000000000002098 | PMID 40424081 Get It

Objective: Patients with inflammatory bowel disease (IBD) are commonly treated with immunosuppressive therapies that increase the risk for infections, including hepatitis B (HepB) virus. Adult patients with IBD have suboptimal seroprotection rates after vaccination with a 3-dose recombinant recombinant HepB vaccine. Heplisav-B is an adjuvanted 2-dose HepB series that is more immunogenic in the general adult population. Herein, we evaluated the immunogenicity of Heplisav-B in adult patients with IBD. Patients and Methods: We conducted a prospective observational study of adult patients with IBD who were not seroprotected to HepB virus and received a Heplisav-B series with postimmunization HepB surface antibody (anti-HBs) serologic testing. Postimmunization anti-HBs ≥10 IU/mL was considered seroprotection. The primary outcome was the rate of seroprotection. Secondary outcomes were rates of seroprotection in different age groups, those on immunosuppressive therapy, and previous HepB vaccine nonresponders using a univariate analysis. Results: Eighty-five patients met the inclusion criteria with the majority (72%) achieving seroprotection with a median anti-HBs level of 48.7 IU/mL and 28 patients (33%) having an anti-HBs level >100 IU/mL. Those on immunosuppressive therapy [49 (58%), 18 nonresponders, odds ratio: 0.34, 95% CI: 0.12-0.99] and primary nonresponders to a previous HepB series [22 (26%), 11 nonresponders, odds ratio: 0.26, 95% CI: 0.09-0.73] were less likely to achieve seroprotection. Seven patients who did not respond received a third dose of Heplisav-B, and 2 achieved seroprotection. Conclusions: Heplisav-B achieved higher rates of seroprotection than those seen with 3-dose recombinant HepB vaccines in patients with IBD and may be the preferred option.